Somerville, MA, United States of America

Ryan D White

This inventor holds 36 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 13 EPO patents, primarily in Beta-Secretase Modulators. Top assignees: Amgen Inc., Vigil Neuroscience, Inc., Teijin Pharma Limited. Active years: 2010-2025.

USPTO Granted Patents = 36 (Patent Applications = 6)

% Patents Active = 77.8

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 13 (Patent Applications = 22)

Average Co-Inventor Count = 7.2

ph-index = 7

Forward Citations = 265(Granted Patents)

Location History:

Somerville, CA (US) (2015)
Somerville, MA (US) (2010 - 2023)
Thousand Oaks, CA (US) (2023 - 2024)

Company Filing History:

Vigil Neuroscience, Inc.

patents

2 out of 126

Teijin Pharma Limited

patents

4. 1 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Beta-Secretase Modulators

Aurora Kinase Modulators

Amino-Oxazine

Thiazine Compounds

Spiro Compounds

Benzimidazole Derivatives

Cyclopropyl Fused Compounds

Pyrazolo Compounds

N-Cyano Derivatives

Benzomorpholine Derivatives

Substituted Pyridone Compounds

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428425 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2025-09-30),

2. 12319691 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2025-06-03),

3. 12252489 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2025-03-18),

4. 11912711 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2024-02-27),

5. 11884675 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2024-01-30),

6. 11718617 - Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use (2023-08-08),

7. 11608344 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2023-03-21),

8. 11572374 - N-cyano-7-azanorbornane derivatives and uses thereof (2023-02-07),

9. 11332459 - Benzimidazole derivatives and their uses (2022-05-17),

10. 9777019 - Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use (2017-10-03),

11. 9725469 - Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use (2017-08-08),

12. 9611261 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-04-04),

13. 9556135 - Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use (2017-01-31),

14. 9550762 - Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-01-24),

15. 9365522 - Pyrazole amide derivative (2016-06-14),

Title: The Innovative Achievements of Inventor Ryan D White

Introduction:

Inventor Ryan D White, based in Somerville, MA, has made significant contributions to the field of medical research with a notable portfolio of 31 patents.

Latest Patents:

White's recent patents focus on heterocyclic compounds as triggering receptor expressed on myeloid cells 2 (TREM2) agonists. These compounds demonstrate utility in the activation of TREM2 and the treatment of neurodegenerative disorders. Pharmaceutical compositions and synthesis intermediates are also disclosed in these patents.

Career Highlights:

With a background in medical research, White has made substantial strides in advancing treatments for neurodegenerative disorders. He has a keen focus on utilizing innovative compounds to target specific biological receptors for therapeutic purposes.

Collaborations:

During his career, White has collaborated with esteemed companies such as Amgen Inc. and Teijin Pharma Limited. His collaborative efforts with individuals like Jason Brooks Human and Oleg Epstein have resulted in groundbreaking research and patent developments.

Conclusion:

In conclusion, Ryan D White's dedication to medical research and innovation is evident in his extensive patent portfolio. His contributions in the field of pharmaceuticals and neurodegenerative disorder treatments continue to pave the way for future advancements in the industry.